Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 07/15/2024.
  • Additional Information
    • Alternate Title:
      Kyverna-Get-FDA-RMAT
    • Subject Terms:
    • Abstract:
      The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option [ABSTRACT FROM PUBLISHER]